CBG(000009)2023-04-14 16:00Dividend and Shareholder Information - The company plans to distribute a cash dividend of 0.35 CNY per 10 shares to all shareholders, based on a total of 2,579,213,965 shares[2]. - The company distributed a cash dividend of ¥0.35 per 10 shares, totaling ¥90,272,488.77, which represents 100% of the total profit distribution[114][115]. - The company reported a total distributable profit of ¥395,102,959.66 at the end of the reporting period[115]. Financial Performance - The company's operating revenue for 2022 was ¥31,998,720,906.66, representing an increase of 82.29% compared to ¥17,553,419,112.71 in 2021[12]. - The net profit attributable to shareholders for 2022 was ¥1,156,580,360.59, an increase of 11.68% from ¥1,035,599,088.75 in 2021[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥680,810,615.67, up 75.72% from ¥387,441,388.95 in 2021[12]. - The net cash flow from operating activities for 2022 was ¥290,476,146.61, a significant improvement from a negative cash flow of ¥279,272,690.50 in 2021, marking a 204.01% increase[12]. - The total assets at the end of 2022 were ¥52,293,310,406.08, a 41.05% increase from ¥37,073,195,202.73 at the end of 2021[13]. - The net assets attributable to shareholders at the end of 2022 were ¥9,133,813,548.67, reflecting a 14.17% increase from ¥8,000,289,198.35 at the end of 2021[13]. - The company achieved a weighted average return on equity of 13.49% in 2022, slightly down from 13.90% in 2021[12]. Business Operations and Strategy - The company reported significant changes in its business scope, including investments in new materials and high-tech industries since 2014[10]. - The company has undergone several changes in its business operations, including real estate development and modern biomedicine projects[10]. - The company is focused on high-tech industries, including new energy materials and electric vehicles, aligning with national strategic initiatives for industry upgrades[20]. - The company plans to continue developing new technologies and expanding its market presence in strategic emerging industries, enhancing its operational capabilities[20]. - The company aims to develop functional health products leveraging existing technology, brand, and channels, while continuously innovating and upgrading its business model[22]. Research and Development - The company reported a significant increase in R&D expenses, totaling ¥1,508,490,891.16, which is an 86.90% increase compared to ¥807,125,218.97 in 2021[49]. - The number of R&D personnel increased to 1,557 in 2022, up 24.86% from 1,247 in 2021[54]. - R&D investment amounted to ¥1,521,111,792.01 in 2022, representing an 87.36% increase from ¥811,884,198.00 in 2021[56]. - The proportion of R&D investment to operating revenue rose to 4.75% in 2022 from 4.63% in 2021, an increase of 0.12%[56]. Environmental Compliance - The company strictly adheres to environmental protection laws and industry standards in its production and operational activities[125]. - The company and its subsidiaries are classified as key pollutant discharging units by environmental protection authorities[125]. - The company has obtained pollution discharge permits for its subsidiaries, ensuring compliance with environmental regulations[126]. - The total COD emissions for 2022 were 0.038 tons, with ammonia nitrogen at 0.0001 tons and phosphate at 0.0005 tons[127]. - The company has implemented measures to ensure that emissions meet the required standards after treatment[128]. Governance and Management - The company maintains a governance structure compliant with legal regulations, ensuring independent operation without major shareholder interference[86]. - The company has established independent financial and operational systems, ensuring no asset misappropriation by major shareholders[86]. - The company has a diverse board with members holding various professional qualifications, including registered accountants and legal professionals[93]. - The company has maintained stability in its leadership with no reported changes in directors or senior management during the reporting period[90]. Market and Industry Challenges - The real estate market faced unprecedented challenges in 2022, but policies are being implemented to stabilize and support the sector[23]. - The biopharmaceutical sector is under pressure from regulatory changes and the need for new business development to ensure sustainable growth[81]. - The company faces risks related to industry policies, technological obsolescence, and supply chain dynamics, with measures in place to mitigate these risks[80]. Legal and Compliance Issues - The total amount involved in the lawsuit against Shenzhen Yuntong Logistics Co., Ltd. and others is approximately 670.72 million RMB, with a claim for full compensation of this amount[145]. - The court has taken preservation measures on assets valued at approximately 670.72 million RMB belonging to the defendants, but the lawsuit has not yet been concluded[145]. - There were no significant penalties or rectifications reported during the reporting period[147]. Shareholder Structure - The company has no controlling shareholder or actual controller since 2009, with the top two shareholders holding 8.34% and 6.95% respectively[10]. - The largest shareholder holds 16.04% of the company, with the second and third largest shareholders holding 15.04% and 5.92% respectively, indicating a diversified ownership structure[86]. - The total number of ordinary shareholders at the end of the reporting period was 226,073[165]. Financial Instruments and Debt Management - The company has issued a total of three bonds, with a total amount raised of CNY 2.05 billion, including CNY 1 billion for the 2017 bond, CNY 300 million for the 2021 bond, and CNY 750 million for the 2022 bond[174][176]. - The company has maintained its debt repayment mechanisms and plans without any changes during the reporting period, ensuring investor rights are protected[178]. - The company has not reported any overdue bonds during the reporting period, indicating a stable financial position[178]. Community Engagement and Social Responsibility - The company donated over 90 million yuan in total for social responsibility initiatives, including 15.6 million yuan worth of medicines to impoverished areas in 2022[138]. - The company organized 68 health events, benefiting over 110,000 community residents with free health check-ups[138]. - The company has committed to ongoing support for rural revitalization efforts, including cash donations and product purchases[138].